All In Biotech

Drug Trial Radar · NCT07631325

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Jul 31, 2028

Study completion Jul 31, 2030

Sponsor

Lead sponsor
John KirkwoodAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Glycyx MOR Inc.
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human study will evaluate the safety, clinical activity, and immunologic effects of combining axelopran with nivolumab in patients with PD-1-refractory unresectable or metastatic cutaneous melanoma. Exploratory analyses incorporating opioid exposure history and post-hoc OPRM1 genotyping will inform future precision immuno-oncology strategies.

Conditions

  • Unresectable Cutaneous Melanoma

Interventions

  • AxelopranDrug

    A peripherally restricted mu-opioid receptor antagonist (PAMORA) designed to mitigate the undesirable peripheral effects of opioids without compromising their central analgesic action.

  • NivolumabDrug

    An immune checkpoint inhibitor that helps the immune system attack cancer cells by blocking PD-1 receptors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events Related to TreatmentTime frame: Up to 30 days post end of treatment
  2. Best objective response rate (BORR)Time frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.